Off-label TAVR for native aortic regurgitation linked to worse outcomes

jenavalve TAVR valve for aortic regurgitation acquired by Edwards

The JenaValve Transcatheter Heart System on display at TCT 2023. Photo by Dave Fornell.

Targeting aortic regurgitation with TAVR valves built to treat aortic stenosis may be the only option a cardiologist has—but valves designed specifically to treat AR are linked to much better outcomes, according to a new meta-analysis. Edwards Lifesciences recently acquired the two companies at the center of this study, JenaValve and JC Medical.